Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for CpG 1018 in Pandemic influenza vaccines. The expected timing is based on the latest available company guidance and may change.
8/7/25- Advance optimal CpG 1018 formulations based on Part 1 results. Top-line immunogenicity and safety data in 2026. 11/05/25:- Part 1 of Ph1/2 H5N1 study completed; advancing optimal CpG 1018 formulations; top-line data still expected in 2026.
Verification
Confirm timing and program details against the company announcement or filing.